Large-Scale Drug Screen Identifies FDA-Approved Drugs for Repurposing in Sickle-Cell Disease

Sickle-cell disease (SCD) is a debilitating hematological disorder with very few approved treatment options. Therapeutic reactivation of fetal hemoglobin (HbF) is one of the most pursued methods for ameliorating the systemic manifestations of SCD. Despite this, very few pharmacological agents have a...

Descripción completa

Detalles Bibliográficos
Autores principales: Cannon, Matthew, Phillips, Hannah, Smith, Sidney, Williams, Katie, Brinton, Lindsey, Gregory, Charles, Landes, Kristina, Desai, Payal, Byrd, John, Lapalombella, Rosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408993/
https://www.ncbi.nlm.nih.gov/pubmed/32708954
http://dx.doi.org/10.3390/jcm9072276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408993/
https://www.ncbi.nlm.nih.gov/pubmed/32708954
http://dx.doi.org/10.3390/jcm9072276

Ejemplares similares